WaveMan
WaveMan · Company
CERO · Cero Therapeutics Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CERO Cero Therapeutics (CERO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001870404
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Cero Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for CERO THERAPEUTICS HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
YK Bioventures Opportunities GP I, LLC
SELL
2024-12-13 SEC
2,998,908
$179.9K
-100.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 12, 2024.
  • The trade is 23.1% of the 13,005,169 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider YK Bioventures Opportunities GP I, LLC sold about $179.9K of CERO on Dec 13, 2024; 1 other insider sold within 30 days.
YK Bioventures Opportunities GP I, LLC
SELL
2024-12-13 SECtraded 2024-12-12
1,614,541
$113.0K
-100.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 11, 2024.
  • The trade is 10.1% of the 16,004,077 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider YK Bioventures Opportunities GP I, LLC sold about $113.0K of CERO on Dec 12, 2024; 1 other insider sold within 30 days.
YK Bioventures Opportunities GP I, LLC
SELL
2024-12-13 SECtraded 2024-12-11
1,343,801
$107.5K
-100.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.6% of the 17,618,618 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider YK Bioventures Opportunities GP I, LLC sold about $107.5K of CERO on Dec 11, 2024; 1 other insider sold within 30 days.
Kossar Mitchell William
SELL
2024-12-10 SEC
1,570,947
$141.4K
-100.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 9, 2024.
  • The trade is 8.3% of the 18,962,419 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider Kossar Mitchell William sold about $141.4K of CERO on Dec 10, 2024; 1 other insider sold within 30 days.
Kossar Mitchell William
SELL
2024-12-10 SECtraded 2024-12-09
850,543
$93.6K
-100.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 6, 2024.
  • The trade is 4.1% of the 20,533,366 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider Kossar Mitchell William sold about $93.6K of CERO on Dec 9, 2024; 1 other insider sold within 30 days.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 3 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CERO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.7%12M
-100%-67%-33%+0%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CERO: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in CERO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CERO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CERO financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
average equity is zero or negative
Return on assets
-402.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
-$296.2K
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2026-03-31, minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122023-122022-122021-12
Operating incomen/a-$7.7M-$2.9Mn/a
Net income-$19.9M-$7.3M-$667.7Kn/a
EPS (diluted)n/a-1,248.64n/an/a
Operating cash flow-$16.1M-$1.5M-$1.1Mn/a
Cashn/a$96.9K$475.9K$1.1M
Buybacksn/a$33.5M$139.4Mn/a
Dividends paid$127.1Kn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

CERO Stock Sonar score 1/7 axes

Find similar shapesCompare
Risk and compliance
96
Inputs
  • Short interest, % of float+0.0% · 96 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
6 not measured: Profitability, Financial health, Growth, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies